

# ChemComm

Chemical Communications

rsc.li/chemcomm



ISSN 1359-7345

**COMMUNICATION**

Jesús Cases Díaz and Mónica Giménez-Marqués  
Alternative protein encapsulation with MOFs: overcoming  
the elusive mineralization of HKUST-1 in water


 Cite this: *Chem. Commun.*, 2024, 60, 51

 Received 1st September 2023,  
Accepted 8th November 2023

DOI: 10.1039/d3cc04320g

rsc.li/chemcomm

# Alternative protein encapsulation with MOFs: overcoming the elusive mineralization of HKUST-1 in water†

 Jesús Cases Díaz and Mónica Giménez-Marqués \*

Protein encapsulation by *in situ* formation of MOFs is a valuable strategy to immobilise and protect these bioentities. However the required biocompatible conditions limits the scope of MOFs under investigation, particularly in the case of hydrolytically unstable MOFs such as HKUST-1. We report alternative synthetic procedures to obtain protein@HKUST-1 biocomposites from related Cu-BTC dense biocomposites. pH dependent dense phase precursors are first obtained and their transformations into HKUST-1 are characterized. Encapsulation efficiency is affected by the protein's nature, and can be modulated by the sequential or simultaneous addition of MOF precursors.

Metal-organic frameworks (MOFs) have been demonstrated as suitable platforms for the immobilization of biomolecules.<sup>1</sup> Their versatile functionality and porosity permit fine-tuning of the host-guest interactions, conferring protection against denaturation and allowing the transport of specific substrates.<sup>2</sup> Among the developed immobilization approaches,<sup>3</sup> *in situ* MOF growth is preferred since avoids biomolecule size limitations and leaching encountered *via* infiltration or surface immobilization, respectively.<sup>4</sup> However, the biocompatible conditions required for mineralization are typically unsuited for the growth of most MOFs. Thus, zeolitic imidazolate frameworks (ZIFs) have been the most exploited materials owing to their optimal stability and facile synthesis under these conditions.<sup>5</sup> Very recently, the progress of biocompatible MOF synthesis has permitted incorporating more structures on the list,<sup>5,6</sup> offering new chemical scenarios at the MOF-biomolecule interface.

Motivated by the difficulty in obtaining specific MOFs by direct synthesis in water, we propose using alternative routes. One of these elusive MOFs is the archetypal HKUST-1, constituted by Cu<sup>2+</sup> cations and benzene 1,3,5-tricarboxylic acid ligands (H<sub>3</sub>BTC).<sup>7</sup> HKUST-1 forms in mixtures of H<sub>2</sub>O:EtOH,<sup>8</sup> a medium that has been employed for the preparation of certain protein@HKUST-1 composites.<sup>4,9</sup> However, its *in situ* growth is prevented in water, forming instead dense

Cu-BTC compounds.<sup>8</sup> In addition, HKUST-1 is degraded in water or dilute HCl to these layered Cu-BTC compounds with negligible porosity. Some of these degradation products can be transformed back to the initial porous phase upon immersion in EtOH.<sup>10</sup> Essentially, the acid degraded material can be converted to HKUST-1 upon EtOH immersion, whereas the water degraded is not transformed. These observations allow us to glimpse an alternative biocompatible HKUST-1 synthetic route for protein encapsulation.

Herein we propose the synthesis of non-porous Cu-BTC materials in water and their later reversible transformation to the porous HKUST-1 phase by immersion in EtOH under specific pH conditions. This biocompatible dense-to-porous reversible transformation enables the formation of elusive protein@HKUST-1 biocomposites in water.


First attempts consisted in the synthesis of Cu-BTC compounds from two aqueous solutions of Na<sub>3</sub>BTC and CuCl<sub>2</sub> (molar ratio 1 : 1) in the presence of different amounts of HCl (0, 0.5 or 1 equivalents) and later incubation in EtOH (Fig. 1). Depending on the acidity of the media, different phases were obtained. In absence of acid (0 eq.), a dense Cu-BTC material that resembles the M<sub>3</sub>(BTC)<sub>2</sub>·12H<sub>2</sub>O (M = Cu, Co, Ni, and Zn)<sup>11,13,14</sup> structure is achieved, as deduced from XRPD (Fig. 1A), with negligible N<sub>2</sub> sorption capacity (Fig. 1B). This phase, termed as **H0**, cannot transform to HKUST-1 upon overnight exposure to EtOH, but can be converted upon acidification with acetic acid (HAc), HCl or the acid ligand H<sub>3</sub>BTC (Fig. S1, ESI†). Addition of HCl (0.5 eq.) leads to a coexistence of the previous H0 phase with a new one denoted as **H1**, with the latter being able to transform into HKUST-1 upon immersion in EtOH (Fig. 1C), with the expected gain in sorption capacity (Fig. 1D). When more HCl is added (1 eq.), only the ethanol transformable phase **H1** is obtained as deduced by XRPD (Fig. 1E) and the expected gain in N<sub>2</sub> sorption capacity (Fig. 1F). This **H1** structure with formula Cu(HBTC)·3H<sub>2</sub>O,<sup>12,15</sup> corresponds to the one obtained by G. Majano *et al.* after degradation of HKUST-1 in water, which is reversibly reconstructed to the starting material upon exposure to EtOH.<sup>10</sup> As a result, two dense layered structures of Cu-BTC, H0 and H1 can be obtained from aqueous solutions depending on the pH. These two phases can be inter-converted (Fig. S2, ESI†) and lately transformed into HKUST-1 upon immersion in EtOH as

Instituto de Ciencia Molecular (ICMol), Universidad de Valencia, Catedrático José Beltrán 2, 46980 Paterna, Valencia, Spain. E-mail: monica.gimenez-marques@uv.es

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3cc04320g>









**Fig. 1** XRPD patterns (left) and  $N_2$  sorption isotherms (right) of Cu-BTC materials synthesized with (A, B) 0 equivalents, (C, D) 0.5 equivalents and (E, F) 1 equivalent of HCl and the corresponding products washed with water ( $ddH_2O$ ), ethanol (EtOH) or ethanol and acid (EtOH +  $H^+$ ). H0: CCDC 609754,<sup>11</sup> H1: CCDC 1288676.<sup>12</sup>

depicted in Fig. 2. The transformed HKUST-1 samples from H0 or H1 are respectively termed **HK0** and **HK1**. Morphological and size particle differences are observed upon transformation in both cases (Fig. S3, ESI<sup>†</sup>). It was found that under these biocompatible conditions, the phase transformations can be reversibly repeated (Fig. S4 and S5, ESI<sup>†</sup>) with a good recovery of the sorption capacity (Fig. S6, ESI<sup>†</sup>).

The possibility of *in situ* protein encapsulation using the alternative HKUST-1 synthesis *via* transformation of dense Cu-BTC phases was explored. With this aim, a variety of proteins including casein (Cas), bovine serum albumin (BSA), subtilisin Carlsberg (SubC), bovine cytochrome *c* (CytC), trypsin (Try) and lysozyme (Ly) were selected, covering a broad range of isoelectric points (pI)



**Fig. 2** Schematic representation of the reversible transformation processes among the different Cu-BTC phases.



**Fig. 3** (A) Encapsulation efficiency obtained for the different proteins with H0 (pI indicated in right axis). (B) Representation of the interactions at the biomolecule surface in presence of (i) an excess or (ii) limited ligand salt, resulting respectively in moderate or significant encapsulation efficiency (metal cations represented as blue spheres). (C) Encapsulation efficiency of lysozyme in H0 as a function of the initial amount of protein and BTC. (D) Encapsulation efficiency of the optimized synthesis for H0 and H1 with the set of proteins.

(Fig. 3A and Table S1, ESI<sup>†</sup>), an electrostatic parameter that has been demonstrated to highly determine the occurrence of surface interactions that promote effective encapsulation.<sup>16</sup> First encapsulation attempts consisted of mixing the protein with a  $Na_3BTC$  aqueous solution, and in a second step, adding the  $CuCl_2$  aqueous solution on top (see ESI<sup>†</sup>). Reasonably good encapsulation efficiencies ( $\sim 81$ – $63\%$ ) were obtained for the low pI proteins, with a significant drop evidenced for the proteins with higher pI ( $\sim 42$ – $33\%$ ) (Fig. 3A). These results are in good agreement with the previously postulated encapsulation mechanism,<sup>4,16,17</sup> which states that MOF formation around the biomolecule depends on the effective interaction between the constituent metal cations and the functional groups on the biomolecule surface, which turns into nucleation points for the MOF growth. These groups are mainly carboxylates in the low pI proteins, or amine and guanidinium groups in the high pI ones, which effectively bind to metal cations, or hamper their interaction, respectively. Following this principle, we have recently established the possibility to dominate these surface interactions by employing hard Lewis acid cations as MOF precursor, obtaining optimal encapsulation efficiencies irrespective of the protein nature for a variety of MIL-100(Fe) biocomposites.<sup>18</sup> As expected, the soft Lewis acid cation used in this work,  $Cu^{2+}$ , results in a compromised encapsulation of basic proteins (Fig. 3A). In this situation, it was hypothesized that the carboxylates from the  $BTC^{-3}$  binding to the available  $Cu^{2+}$  may strongly hamper an effective interaction at the biomolecule interface especially in the high pI proteins, which is then reflected in a reduced encapsulation efficiency (Fig. 3B).

To gain more insight into the actual interactions at the biomolecule-MOF interface, we thoroughly analyzed the hindered biocomposite formation using the highly basic Ly (pI 11.35)<sup>19</sup> protein as model. A systematic study was carried out by adding the corresponding metal and ligand precursor aqueous solutions (1:1 ratio) on top of a Ly aqueous solution with increasing amounts of protein



(see ESI† for details).  $\text{CuCl}_2$  aqueous solution (50 mM) was added at a fixed rate, whereas a varying percentage of the BTC solution (50 mM) was added beforehand. The rest of the BTC solution was added in the same timelapse than the  $\text{CuCl}_2$ . With these conditions, it is possible to cover the situations where BTC is added in different amounts prior to the synthesis. The results depicted in Fig. 3C show that the encapsulation efficiency rapidly decays as more BTC is added before the synthesis, with the highest encapsulation efficiency ( $\sim 85\%$ ) reached when BTC and  $\text{CuCl}_2$  precursor solutions are added simultaneously on top of a pure protein aqueous solution. In addition, a limited uptake capacity is shown since the encapsulation efficiency decays with the amount of added protein. The optimized procedure was extended for the rest of proteins with H0 and H1 dense phases. As a general trend, higher encapsulation efficiencies were found in all cases, with the exception of SubC (Fig. 3D). The Cu-BTC phases obtained in presence of the proteins are identical to the ones obtained in its absence for both H0 and H1 (Fig. 4B and C), even though some of the H0 samples, like Cas and Ly biocomposites exhibit additional peaks at  $7.7^\circ$ ,  $9.2^\circ$  and  $12.0^\circ$ . This pattern has been previously reported as a humidity and temperature dependent degradation product of HKUST-1.<sup>20</sup>

Essentially, the optimized synthetic scheme to obtain protein@HKUST-1 biocomposites consist in the encapsulation of proteins in H0 or H1, and their subsequent transformation to the porous HK0 or HK1 by immersion in ethanol solutions (Fig. 4A). The *in situ* synthesis of the dense phases in presence of the proteins does not alter their transformation process, yielding in all cases HKUST-1 (Fig. 4D and E). This transformation was also confirmed by ATR-FTIR spectroscopy, (Fig. S7, ESI†) where the initial H0 and H1 phases with clearly different spectra, lead to similar HKUST-1 spectra after transformation. Protein loadings were estimated from TGA analysis (Fig. S8, ESI†), resulting in values ranging from  $\sim 7$  to  $\sim 13\%$ , except for SubC@HK1, with a lower encapsulation efficiency and a lower loading ( $\sim 5\%$ ) (Tables S2 and S3, ESI†).  $\text{N}_2$  sorption studies were conducted to monitor the changes in specific surface. In all cases, a lower sorption capacity is obtained for the composites (Fig. S9 and Table S4, ESI†) as compared to the control empty material, with BET values dropping from 1529 to  $\sim 1100\text{--}1350\text{ m}^2\text{ g}^{-1}$  respectively for HK0 and the corresponding protein@HK0 materials, and from 1611 to  $\sim 1150\text{--}1350\text{ m}^2\text{ g}^{-1}$  respectively for HK1 and the protein@HK1 materials. Morphological characterization by TEM revealed the poly-disperse nature of the samples (Fig. S10 and S11, ESI†).

The impact of protein encapsulation within dense (H0, H1) and their corresponding transformed porous phases (HK0, HK1) was evaluated by analyzing the activity of encapsulated CytC (MW 12.23 kDa, hydrodynamic diameter of 3.4 nm) a small protein involved in electron transfer in aerobic and anaerobic respiration.<sup>21</sup> The redox ability was measured employing  $\text{H}_2\text{O}_2$  and 3,3',5,5'-tetramethylbenzidine (TMB) as substrates. H1 and related HK1 phases were preferred for further investigations, as CytC@H0 composite shows poor stability upon long term storage. H1 and HK1 control materials exhibit little peroxidase activity, attributed to the constitutive  $\text{Cu}^{2+}$  present in both materials (Fig. 5A).<sup>22–24</sup> In the case of the biocomposites, CytC@H1 exhibits a similar activity than H1, while CytC@HK1 reveals a sharp activity enhancement, which is attributed to its characteristic permanent porosity that




Fig. 4 (A) Schematic representation of the protein@HKUST-1 synthetic procedure. XRPD patterns of the (B) protein@H0, (C) protein@H1, (D) protein@HK0 and (E) protein@HK1 biocomposites.


enables the transfer of substrates. Control analysis over the physical mixtures reveal that combination of CytC and H1 perform as free CytC (Fig. S12a, ESI†), whereas mixing of CytC and HK1 has a comparable activity than the related biocomposite, CytC@HK1. This trend is also observed in CytC@HK0 measured 24 h after synthesis (Fig. 5B).

In view of the activity increase in both the CytC@HK1 and its related physical mixture (Table S5, ESI†), an interfacial activation is proposed.<sup>25,26</sup> This mechanism was evidenced with a control experiment using the mixture of CytC and  $\text{Cu}(\text{OAc})_2$ , revealing a similar activity than the sum of CytC and  $\text{Cu}(\text{OAc})_2$  and therefore dismissing an activator role for  $\text{Cu}^{2+}$  (Fig. S12b, ESI†). Thus, the synergistic effect observed on CytC@HK1 is attributed to the interaction of CytC with the HKUST-1. Similar peroxidase increase for CytC has been observed in Cu-based systems,<sup>27</sup> as well as in MOFs<sup>28</sup> and HOFs.<sup>29</sup>

In addition, it was found that  $\text{Cu}^{2+}$  exerts a negative impact in the activity of encapsulated SubC and Try proteases (Fig. S13 and S14a, ESI†), an inhibition that can be reversed to some extent when the protein is incubated with optimal concentrations of a chelating agent, EDTA (Fig. S14b and c, ESI†). Analogous enzymatic inhibition was observed for different enzymes in Cu-terephthalate systems,<sup>30</sup> as many of them have reported  $\text{Cu}^{2+}$  inhibition,<sup>31,32</sup> which indicates that HKUST-1 support may not be appropriate for certain proteins.

The effect of encapsulation was also evaluated with Ly, which retained a  $\sim 90\%$  of lysolytic activity as compared with the free form (Fig. 5C). In addition, the scaffold provides some degree of protection to external agents, as temperature or





**Fig. 5** (A) Kinetic analysis of the free CytC, encapsulated CytC and CytC + MOFs physical mixtures. (B) Relative activity of CytC@HK0 and CytC@HK1 biocomposites ( $H_2O_2$  3.27 mM). (C) Lysolytic activity retained by encapsulated Ly after exposure to different conditions. (D) Proteolysis of free azocasein, azocasein and HKUST-1 physical mixture, and encapsulated azocasein after treatment with protease.

organic solvents (Fig. 5C), but most importantly, acts as a shell against proteases, as proved by the protection of the dyed derivative of casein, azocasein (Fig. 5D), thus validating the preferred encapsulation vs physical adsorption.

In summary, an alternative synthetic procedure to obtain protein@HKUST-1 composites using protein@Cu-BTC dense composites as precursors are presented. Essentially, a pH dependent *in situ* formation of H0 ( $Cu_3(BTC)_2 \cdot 12H_2O$ ) or H1 ( $Cu(HBTC) \cdot 3H_2O$ ) and their direct transformations into HKUST-1 are reported. A systematic study with six different proteins reveals that encapsulation efficiency is directly affected by the pI of the protein, but also relies on the sequential or simultaneous addition of the MOF precursors. Characterization of the biocomposites demonstrate that the solid matrix confers protection against protein denaturation by organic solvents and proteolytic agents. The dense-to-porous reversible transformation enables fine-tuning of encapsulated CytC activity (4-fold increase) as a result of the change in mass transport across the support. We believe this alternative route will disclose new possible pathways for biomolecule encapsulation to overcome the elusive mineralization process of most MOFs.

This work has been supported by TED2021-132729A-I00 and PID2020-118564GA-I00 grants, funded by MCIN/AEI/10.13039/501100011033 and NextGenerationEU/PRTR, Generalitat Valenciana (PROMETEO CIPROM/2022/48), and 2022 Leonardo Grant, BBVA Foundation. M. G.-M. thank MICINN for a Ramón y Cajal (RYC2019-027902-I) fellowship.

## Conflicts of interest

There are no conflicts to declare.

## Notes and references

- V. Lykourinou, Y. Chen, X. Wang, L. Meng, T. Hoang, L. Ming, R. L. Musselman and S. Ma, *J. Am. Chem. Soc.*, 2011, **133**, 10382–10385.
- F. Lyu, Y. Zhang, R. N. Zare, J. Ge and Z. Liu, *Nano Lett.*, 2014, **14**, 5761–5765.
- C. Doonan, R. Riccò, K. Liang, D. Bradshaw and P. Falcaro, *Acc. Chem. Res.*, 2017, **50**, 1423–1432.
- K. Liang, R. Riccò, C. M. Doherty, M. J. Styles, S. Bell, N. Kirby, S. Mudie, D. Haylock, A. J. Hill, C. J. Doonan and P. Falcaro, *Nat. Commun.*, 2015, **6**, 4–11.
- S. Kumari, R. N. Ehrman and J. J. Gassensmith, *Matter*, 2023, **6**, 2570–2573.
- D. Jordahl, Z. Armstrong, Q. Li, R. Gao, W. Liu, K. Johnson, W. Brown, A. Scheiwiller, L. Feng, A. Ugrinov, H. Mao, B. Chen, M. Quadir, H. Li, Y. Pan and Z. Yang, *ACS Appl. Mater. Interfaces*, 2022, **14**(46), 51619–51629.
- S. S. Y. Chui, S. M. F. Lo, J. P. H. Charmant, A. G. Orpen and I. D. Williams, *Science*, 1999, **283**, 1148–1150.
- B. Zhang, J. Zhang, C. Liu, X. Sang, L. Peng, X. Ma, T. Wu, B. Han and G. Yang, *RSC Adv.*, 2015, **5**, 37691–37696.
- Y. Mao, J. Li, W. Cao, Y. Ying, P. Hu, Y. Liu, L. Sun, H. Wang, C. Jin and X. Peng, *Nat. Commun.*, 2014, **5**, 5532.
- G. Majano, O. Martin, M. Hammes, S. Smeets, C. Baerlocher and J. Pérez-Ramírez, *Adv. Funct. Mater.*, 2014, **24**, 3855–3865.
- Q.-W. Zhang and G.-X. Wang, *Z. Kristallogr. - New Cryst. Struct.*, 2006, **221**, 101–102.
- R. Pech and J. Pickardt, *Acta Crystallogr., Sect. C: Cryst. Struct. Commun.*, 1988, **44**, 992–994.
- O. M. Yaghi, H. Li and T. L. Groy, *J. Am. Chem. Soc.*, 1996, **118**, 9096–9101.
- A. Nowacka, P. Briantais, C. Prestipino, F. X. Llabrés and I. Xamena, *Cryst. Growth Des.*, 2019, **19**, 4981–4989.
- Y.-H. Ma, P.-Z. Ma, T. Yao and J.-T. Hao, *Acta Crystallogr., Sect. E: Struct. Rep. Online*, 2013, **69**, m538.
- N. K. Maddigan, A. Tarzia, D. M. Huang, C. J. Sumby, S. G. Bell, P. Falcaro and C. J. Doonan, *Chem. Sci.*, 2018, **9**, 4217–4223.
- G. Chen, X. Kou, S. Huang, L. Tong, Y. Shen, W. Zhu, F. Zhu and G. Ouyang, *Angew. Chem., Int. Ed.*, 2020, **59**, 2867–2874.
- J. Cases Díaz, B. Lozano-Torres and M. Giménez-Marqués, *Chem. Mater.*, 2022, **34**, 7817–7827.
- L. R. Wetter and H. F. Deutsch, *J. Biol. Chem.*, 1951, **192**, 237–242.
- J. B. DeCoste, G. W. Peterson, B. J. Schindler, K. L. Killips, M. A. Browe and J. J. Mahle, *J. Mater. Chem. A*, 2013, **1**, 11922–11932.
- N. Mirkin, J. Jaconic, V. Stojanoff and A. Moreno, *Proteins: Struct., Funct., Bioinf.*, 2008, **70**, 83–92.
- M. Hesari, R. Jia and M. V. Mirkin, *ChemElectroChem*, 2022, **9**, 5–9.
- L. Chen, C. Lin, X. Shi, L. Zhang and D. Sun, *ACS Appl. Nano Mater.*, 2023, **6**, 3835–3847.
- X. Li, L. Gao and Z. Chen, *Spectrochim. Acta, Part A*, 2019, **213**, 37–41.
- R. C. Rodrigues, C. Ortiz, Á. Berenguer-Murcia, R. Torres and R. Fernández-Lafuente, *Chem. Soc. Rev.*, 2013, **42**, 6290–6307.
- T. Zisis, P. L. Freddolino, P. Turunen, M. C. F. Van Teeseling, A. E. Rowan and K. G. Blank, *Biochemistry*, 2015, **54**, 5969–5979.
- Z. Li, Y. Ding, S. Li, Y. Jiang, Z. Liu and J. Ge, *Nanoscale*, 2016, **8**, 17440–17445.
- Y. Chen, F. Jimenez-Ángeles, B. Qiao, M. D. Krzyaniak, F. Sha, S. Kato, G. Gong, C. T. Buru, Z. Chen, X. Zhang, N. C. Gianneschi, M. R. Wasielewski, M. O. De La Cruz and O. K. Farha, *J. Am. Chem. Soc.*, 2020, **142**, 18576–18582.
- G. Chen, L. Tong, S. Huang, S. Huang, F. Zhu and G. Ouyang, *Nat. Commun.*, 2022, **13**, 4816.
- Z. Li, H. Xia, S. Li, J. Pang, W. Zhu and Y. Jiang, *Nanoscale*, 2017, **9**, 15298–15302.
- Y. Wu, L. Chu, W. Liu, L. Jiang, X. Chen, Y. Wang and Y. Zhao, *RSC Adv.*, 2017, **7**, 47309–47315.
- Y. Xianyu, K. Zhu, W. Chen, X. Wang, H. Zhao, J. Sun, Z. Wang and X. Jiang, *Anal. Chem.*, 2013, **85**, 7029–7032.

